Delcath Systems, Inc.
NASDAQ: DCTH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Gerard J. Michel
- Employees
- 96
- Headquarters
- New York City, United States
- IPO year
- 2018
- Market cap
- $422.5M
- Website
- https://www.delcath.com
Loading DCTH…
Loading profile data…Frequently asked questions about DCTH
What does Delcath Systems, Inc. (DCTH) do?
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver....
Where does DCTH trade?
Delcath Systems, Inc. (DCTH) trades on the NASDAQ Capital Market.
What sector is DCTH in?
Delcath Systems, Inc. (DCTH) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Delcath Systems, Inc.?
Gerard J. Michel is the chief executive officer of Delcath Systems, Inc. (DCTH).
Where is Delcath Systems, Inc. headquartered?
Delcath Systems, Inc. is headquartered in United States.
Does DCTH pay a dividend?
Delcath Systems, Inc. (DCTH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DCTH go public?
Delcath Systems, Inc. (DCTH) completed its initial public offering in 2018.